Sapkota S, Baig S, Hess T, et al. - This study was conducted to investigate management practices for glucocorticoid (GC)-induced osteoporosis (GIOP) in systemic lupus erythematosus (SLE) patients utilizing 2017 American College of Rheumatology guidelines as a gold standard. Between 2011 and 2016, researchers performed a retrospective cohort study using a clinical database from the years. A sum of 203 SLE individuals were recruited. They distinguished SLE cases with >90 days continuous prednisone use at doses of ≥7.51 mg daily. Via chart review, osteoporosis risk factors were evaluated. The Fracture Risk Assessment (FRAX) score was calculated for individuals > 40 years of age. Through chart review, vitamin D, bisphosphonate prescriptions, and osteoporotic (OP) fractures were determined. A classification tree was applied to distinguish the key patient-related predictors of bisphosphonate prescription. The data showed that fewer SLE individuals with or at risk for GIOP are prescribed vitamin D and bisphosphonates than suggested by the 2017 ACR guidelines in clinical practice. Despite not having an indication per the ACR guidelines, another 10% were prescribed a bisphosphonate. Individuals were most assuring to receive a bisphosphonate prescription whether they had a major OP FRAX score of > 23.5%.